Acute Myeloid Leukemia: Symptoms, Diagnosis, and Advanced Treatments Using FLT3 Therapeutics in BIS Research

  • Sept. 13, 2022, 1:21 a.m.
  • |
  • Public

The advancement of the global FLT3 inhibitors market has been fueled by the pharmaceutical industry.The potential of FLT3 inhibitors as therapeutic agents for the treatment of blood malignancies with FLT3 positive mutations is currently being assessed in 76 clinical studies. The most advanced medications in the pipeline include SKLB1028, Dovitinib, and Crenolanib.

Due to factors such as the introduction of novel FLT3 medication products, increasing incidence of acute myeloid leukemia, and rising research and development investments, the market is expected to grow significantly.

No comments.

You must be logged in to comment. Please sign in or join Prosebox to leave a comment.